- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 246529-22-6] Icomidocholicacid
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-19796 |
| Brand: | MCE |
| CAS: | 246529-22-6 |
Overview
| MDL | - |
|---|---|
| Molecular Weight | 702.10 |
| Molecular Formula | C44H79NO5 |
| SMILES | C[C@H](CCC(O)=O)[C@H]1CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@@H](NC(CCCCCCCCCCCCCCCCCCC)=O)CC[C@]4(C)[C@@]3([H])C[C@H](O)[C@]12C |
Summary
Icomidocholic acid (Aramchol) is a conjugate of cholic acid and arachidic acid that could inhibit stearoyl coenzyme A desaturase 1 (SCD1) activity. Icomidocholic acid has potential use in nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) treatment [1] .
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT02325492 | Galmed Pharmaceuticals Ltd |
Gallstones
|
October 2014 | Phase 2 |
| NCT02279524 | Galmed Research and Development, Ltd.|Sharp Clinical Services|Diamond Pharma Services Regulatory Affairs Consultancy|Fondazione IRCCS Ca´ Granda, Ospedale Maggiore Policlinico|ClinIntel|Itamar-Medical, Israel|One Way Liver OWL|Medical University of Graz|Tel-Aviv Sourasky Medical Center|DSG EDC|TransPerfect|Clinical Reference Laboratory|Galmed Pharmaceuticals Ltd |
Fatty Liver|Non-Alcoholic Steatohepatitis|Liver Diseases|Liver Fibroses
|
April 29, 2015 | Phase 2 |
| NCT02374437 | Galmed Pharmaceuticals Ltd |
Healthy Volunteers
|
April 2014 | Phase 1 |
| NCT01094158 | Galmed Medical Reserch|Tel-Aviv Sourasky Medical Center|Beilinson Hospital, Petach Tikva,Israel|Meir Medical Center|Kaplan Hospital ,Rehovot,Israel|Soroka Hospital,Beer Sheva,Israel|Hadassah Medical Organization|Hillel Yaffe Medical Center|Rambam Hospital, Haifa, Israel|The Lady Davis Carmel Medical Center|Holy Family Hospital, Nazareth, Israel|Ziv Hospital |
Non-Alcoholic Fatty Liver Disease|Nonalcoholic Steatohepatitis|Metabolic Syndrome
|
November 2010 | Phase 2 |
| NCT03774173 | Galmed Pharmaceuticals Ltd|Hammersmith Medicines Research|Analyst Research Laboratories|Diamond Pharma Services Regulatory Affairs Consultancy |
Healthy
|
December 8, 2018 | Phase 1 |
| NCT04104321 | Galmed Research and Development, Ltd.|Galmed Pharmaceuticals Ltd |
Nonalcoholic Steatohepatitis (NASH)
|
September 23, 2019 | Phase 3 |
| NCT02803996 | Galmed Pharmaceuticals Ltd|WCCT Global|Alpha IRB|Analyst Research Laboratories|Kramer Consulting, LLC|Diamond Pharma Services Regulatory Affairs Consultancy |
Healthy Volunteers
|
May 2016 | Phase 1 |
| NCT04480827 | Galmed Research and Development, Ltd.|Galmed Pharmaceuticals Ltd |
Hepatic Impairment
|
January 22, 2020 | Phase 1 |
| NCT02684591 | University of California, San Diego |
Nonalcoholic Fatty Liver Disease|HIV
|
January 2016 | Phase 2 |
| NCT00776841 | Galmed Medical Reserch |
Healthy
|
September 2008 | Phase 1 |
| NCT03760848 | Galmed Pharmaceuticals Ltd|Hammersmith Medicines Research|Analyst Research Laboratories|Alderley Analytical|Diamond Pharma Services Regulatory Affairs Consultancy |
Healthy
|
November 12, 2018 | Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 25 mg/mL ( 35.61 mM ; Need ultrasonic)
H 2 O : < 0.1 mg/mL (insoluble)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.4243 mL | 7.1215 mL | 14.2430 mL |
| 5 mM | 0.2849 mL | 1.4243 mL | 2.8486 mL |
| 10 mM | 0.1424 mL | 0.7121 mL | 1.4243 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.08 mg/mL (2.96 mM); Clear solution
References
- [1] Safadi R, et al. The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014 Dec;12(12):2085-91.e1.
- [2] Iruarrizaga-Lejarreta M, et al. Role of Aramchol in steatohepatitis and fibrosis in mice. Hepatol Commun. 2017 Nov;1(9):911-927.
Synonyms
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.